HK1205252A1 - 鑑別具有治療性皮脂抑制活性的 受體的配體的方法以及所述配體 - Google Patents

鑑別具有治療性皮脂抑制活性的 受體的配體的方法以及所述配體

Info

Publication number
HK1205252A1
HK1205252A1 HK15105467.6A HK15105467A HK1205252A1 HK 1205252 A1 HK1205252 A1 HK 1205252A1 HK 15105467 A HK15105467 A HK 15105467A HK 1205252 A1 HK1205252 A1 HK 1205252A1
Authority
HK
Hong Kong
Prior art keywords
ahr
ligands
therapeutic
receptor
identifying
Prior art date
Application number
HK15105467.6A
Other languages
English (en)
Inventor
Jean Hilaire Saurat
Original Assignee
Thesan Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thesan Pharmaceuticals Inc filed Critical Thesan Pharmaceuticals Inc
Publication of HK1205252A1 publication Critical patent/HK1205252A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK15105467.6A 2012-05-15 2015-06-09 鑑別具有治療性皮脂抑制活性的 受體的配體的方法以及所述配體 HK1205252A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12168121.7A EP2664919A1 (fr) 2012-05-15 2012-05-15 Une méthode pour identifier les ligands du récepteur AhR possédant une activité sebosuppressive thérapeutique
PCT/IB2013/053979 WO2013171696A1 (en) 2012-05-15 2013-05-15 Method for identifying ligands of the ahr receptor having therapeutic sebosuppressive activity, and said ligands

Publications (1)

Publication Number Publication Date
HK1205252A1 true HK1205252A1 (zh) 2015-12-11

Family

ID=46801377

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15105467.6A HK1205252A1 (zh) 2012-05-15 2015-06-09 鑑別具有治療性皮脂抑制活性的 受體的配體的方法以及所述配體

Country Status (19)

Country Link
US (2) US9480674B2 (zh)
EP (2) EP2664919A1 (zh)
JP (1) JP6254580B2 (zh)
KR (1) KR20150022827A (zh)
CN (1) CN104471391B (zh)
AU (1) AU2013261093A1 (zh)
BR (1) BR112014028307A2 (zh)
CA (1) CA2873191A1 (zh)
CO (1) CO7240392A2 (zh)
HK (1) HK1205252A1 (zh)
IL (1) IL235449A (zh)
IN (1) IN2014DN10283A (zh)
MX (1) MX2014013925A (zh)
NZ (1) NZ702357A (zh)
PH (1) PH12014502548A1 (zh)
RU (1) RU2014150505A (zh)
SG (1) SG11201407405VA (zh)
WO (1) WO2013171696A1 (zh)
ZA (1) ZA201408826B (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2082736A1 (fr) 2008-01-23 2009-07-29 Jean Hilaire Saurat Composition pharmaceutique à usage topique
EP3360560A1 (en) 2012-03-17 2018-08-15 The Regents of the University of California Composition for treating acne
EP2664919A1 (fr) 2012-05-15 2013-11-20 Jean Hilaire Saurat Une méthode pour identifier les ligands du récepteur AhR possédant une activité sebosuppressive thérapeutique
EP3177365A4 (en) * 2014-08-06 2018-01-10 Thesan Pharmaceuticals, Inc. Agonists of the ahr receptor pathway having sebosuppressive activity and a method for identifying said agonists
JP2016150916A (ja) * 2015-02-17 2016-08-22 株式会社マンダム 皮脂分泌抑制剤
EP3167892A1 (en) 2015-11-10 2017-05-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for preventing or treating imflammatory bowel diseases
KR20190017751A (ko) 2016-04-21 2019-02-20 네이키드 바이옴, 인크. 피부 장애의 치료를 위한 조성물 및 방법
US11596657B2 (en) 2016-10-04 2023-03-07 Institut National De La Recherche Agronomique Use of AhR agonist for the preventive or curative treatment of metabolic syndrome and the associated disorders
EP3715471A1 (en) 2019-03-29 2020-09-30 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Ahr signature marker set
EP3875098A1 (en) 2020-03-04 2021-09-08 Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement Use of coprococcus bacteria for the treatment of metabolic syndrome and inflammatory bowel diseases
WO2023064489A1 (en) * 2021-10-14 2023-04-20 Galileo Biosystems, Inc. Aryl hydrocarbon receptor (ahr) modulators and therapeutic uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0614353A1 (en) * 1991-11-25 1994-09-14 Richardson-Vicks, Inc. Compositions for regulating skin wrinkles and/or skin atrophy
AU3002299A (en) * 1998-03-16 1999-10-11 Procter & Gamble Company, The Methods for regulating skin appearance
CA2408152A1 (en) * 2000-05-05 2001-11-15 Wisconsin Alumni Research Foundation Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy
US6902881B2 (en) * 2000-10-13 2005-06-07 President And Fellows Of Harvard College Compounds and methods for regulating cell differentiation
US20030166583A1 (en) * 2002-02-22 2003-09-04 Oliver Yoa-Pu Hu Dermal cytochrome P450 1A inhibitors and enhancers
EP1418164A1 (en) 2002-11-07 2004-05-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) New stilbene derivatives and their use as aryl hydrocarbon receptor ligand antagonists
FR2849597B1 (fr) * 2003-01-08 2006-12-08 Oreal Composition cosmetique pour le soin des peaux grasses, contenant un acide gras carboxylique ou l'un de ses derives
WO2006072203A1 (fr) * 2005-01-05 2006-07-13 Oliver Yoa-Pu Hu Inhibiteur ou promoteur de l’uridinediphosphate-glucuronosyltransferase2b (ugt2b)
US20060210524A1 (en) * 2005-03-18 2006-09-21 Mower Thomas E Skin care composition
US20060210515A1 (en) * 2005-03-18 2006-09-21 Mower Thomas E Hair growth formula
DE102005056890A1 (de) 2005-11-28 2007-05-31 Institut für Umweltmedizinische Forschung gGmbH Kosmetisches Verfahren zur Beeinflussung der Melaninbildung in der Haut
KR100798252B1 (ko) * 2006-01-18 2008-01-24 주식회사 엘지생활건강 ｃ-Ｋｉｔ 활성 저해제, 피부미백제 및 이를 함유하는피부미백용 조성물
DE102006011747A1 (de) * 2006-03-13 2007-09-27 Symrise Gmbh & Co. Kg Dermatologische und/oder kosmetische Zubereitungen
EP1842541A1 (en) * 2006-03-29 2007-10-10 G.I.M.-Gesellschaft Für Innovative Medizin Gmbh Nfg Ohg Plant components and extracts and uses thereof
WO2007128725A1 (en) 2006-05-03 2007-11-15 Symrise Gmbh & Co. Kg 6h-benzofuro[3,2-c] [1]benzopyran and [2] benzopyrano [4,3-b] [1]benzopyran derivatives and wood extracts of these compounds as aryl hydrocarbon receptor (ahr) antagonists for the prevention of uv-b induced skin damage
US20080317684A1 (en) * 2006-09-06 2008-12-25 Isw Group, Inc. Topical Compositions
EP2082736A1 (fr) 2008-01-23 2009-07-29 Jean Hilaire Saurat Composition pharmaceutique à usage topique
WO2011069860A1 (en) * 2009-12-08 2011-06-16 Chr. Hansen A/S Novel use for the treatment of metabolic endotoxemia
KR20110139397A (ko) * 2010-06-23 2011-12-29 건국대학교 산학협력단 다약제 내성 저해 활성을 갖는 5,6-벤조플라본 화합물, 그의 제조 방법 및 이를 유효성분으로 포함하는 다약제 내성 저해용 조성물
CN101953838A (zh) * 2010-08-13 2011-01-26 李岱 吴茱萸次碱用于治疗银屑病的应用
EP2664919A1 (fr) 2012-05-15 2013-11-20 Jean Hilaire Saurat Une méthode pour identifier les ligands du récepteur AhR possédant une activité sebosuppressive thérapeutique

Also Published As

Publication number Publication date
CN104471391A (zh) 2015-03-25
JP2015523553A (ja) 2015-08-13
US9480674B2 (en) 2016-11-01
KR20150022827A (ko) 2015-03-04
SG11201407405VA (en) 2014-12-30
PH12014502548A1 (en) 2015-01-21
EP2850429A1 (en) 2015-03-25
NZ702357A (en) 2016-10-28
BR112014028307A2 (pt) 2017-07-18
JP6254580B2 (ja) 2017-12-27
EP2664919A1 (fr) 2013-11-20
MX2014013925A (es) 2015-05-11
IL235449A (en) 2017-07-31
WO2013171696A1 (en) 2013-11-21
US20170042856A1 (en) 2017-02-16
RU2014150505A (ru) 2016-07-10
IN2014DN10283A (zh) 2015-08-07
US20150057343A1 (en) 2015-02-26
CN104471391B (zh) 2016-12-07
CA2873191A1 (en) 2013-11-21
AU2013261093A1 (en) 2014-12-18
CO7240392A2 (es) 2015-04-17
ZA201408826B (en) 2016-09-28

Similar Documents

Publication Publication Date Title
HK1205252A1 (zh) 鑑別具有治療性皮脂抑制活性的 受體的配體的方法以及所述配體
IL238945A0 (en) System and method for optogenetic therapy
HK1204909A1 (zh) 治療墊系統和方法
EP2833971A4 (en) METHOD, SYSTEM AND USE OF THERAPEUTIC ULTRASOUND
EP2888441A4 (en) SYSTEM AND METHOD FOR PERFORMING STIMULATION OPERATIONS
EP2830702A4 (en) NEUROMODULATION SYSTEM AND RELATED METHODS
SG10201609812SA (en) System and process for retina phototherapy
EP2895120A4 (en) SYSTEMS AND METHOD FOR HAPTIC STIMULATION
EP2906151A4 (en) HEART TREATMENT SYSTEM AND METHOD
EP2887862A4 (en) CLINICAL SUPPORT SYSTEM AND METHOD
EP2852349A4 (en) PROCESS PLANNING SYSTEM
EP2766748A4 (en) SYSTEM AND METHOD FOR REALIZING STIMULATION OPERATIONS
EP2750796A4 (en) HIGH ACTIVITY CATALYST FOR HYDROSILYLATION REACTIONS AND METHODS OF MAKING THE SAME
HK1198622A1 (zh) 用於增强大腦活動的方法和裝置
GB201316148D0 (en) Repositionable control system and method for using the same
EP2862620A4 (en) SYSTEM FOR TREATING DISCHARGE GAS
EP2911746A4 (en) PROTON TREATMENT SYSTEM FRAMEWORK
EP2891465A4 (en) MEDICAL SYSTEM AND METHOD OF OPERATION
HK1215173A1 (zh) 治療金黃色葡萄球菌相關疾病的方法
HK1208503A1 (zh) 用於測定去纖維蛋白多核苷酸的生物活性的基於優球蛋白的方法
GB201215012D0 (en) Patient repositioning system
HK1205095A1 (zh) 用於製備藥物試劑的方法和中間體
EP2777576A4 (en) TREATMENT SYSTEM
EP2789306A4 (en) TREATMENT SYSTEM
EP2803328A4 (en) TREATMENT SYSTEM